Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen

  • Torsten Haferlach
  • Susanne Schnittger
  • Claudia Schoch
Part of the Molekulare Medizin book series (MOLMED)


Unter dem Oberbegriff der chronischen myeloproliferativen Erkrankungen (CMPE) fassen wir
  • die chronische myeloische Leukämie (CML),

  • die Polycythaemia vera (PV),

  • die idiopathische Osteomyelofibrose (OMS) und

  • die essenzielle Thrombozythämie (ET)

zusammen. Die CMPE treten sporadisch auf, gehen somit auf erworbene und nicht auf angeborene klonale genetische Veränderungen zurück. In allen Fällen sind als Ausgangszellen pluripotente hämatopoetische Stammzellen anzunehmen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954–2970PubMedGoogle Scholar
  2. Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloprolifearative disorders. Baillieres Clin Haematol 11:819–848PubMedCrossRefGoogle Scholar
  3. Ben Neriah Y, Daley GQ, Mes Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212–214CrossRefGoogle Scholar
  4. Bennett JM, Catovsky D, Daniel MT et al. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposal by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87:746–754PubMedCrossRefGoogle Scholar
  5. Berk D, Goldberg JD, Donovan PB, Fruchtman SM, Berlin MI, Wasserman LR (1986) Therapeutic recommendations in polycythemia vera based on polycythemia study group protocols. Semin Hematol 23:132–143PubMedGoogle Scholar
  6. Blanchard KL, Gilliland DG, Bunn HF (1992) Clonality in myeloproliferative disorders. Am J Med Sci 304:125–130PubMedCrossRefGoogle Scholar
  7. Chissoe SL, Bodenteich A, Wang YF et al. (1995) Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27:67–82PubMedCrossRefGoogle Scholar
  8. Chronic Myeloid Leukemia Trialist’s Collaborative Group (1997) Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616–1620CrossRefGoogle Scholar
  9. Clift RA, Appelbaum FR, Thomas ED (1993) Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954–1956PubMedGoogle Scholar
  10. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830PubMedCrossRefGoogle Scholar
  11. Davis RL, Konopka JB, Witte ON (1985) Activation of the c-abl oncogene by viral transduction generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 5:204–213PubMedGoogle Scholar
  12. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356PubMedGoogle Scholar
  13. Demory JL, Dupriez B, Fenaux P et al. (1988) Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855PubMedGoogle Scholar
  14. Derderian PM, Kantarjian HM, Talpaz M (1993) Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94:69–74PubMedCrossRefGoogle Scholar
  15. Druker BJ, Sawyers CL, Kantarjian H et al. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 344:1038–1042PubMedCrossRefGoogle Scholar
  16. Druker BJ, Talpaz M, Resta DJ et al. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037PubMedCrossRefGoogle Scholar
  17. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC (1990) Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 75:188–194PubMedCrossRefGoogle Scholar
  18. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172PubMedCrossRefGoogle Scholar
  19. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase avctivity and induction of proteasome-mediated degradation. Mol Cel Biol 15:3547–3557CrossRefGoogle Scholar
  20. Gale RE, Hehlmann R, Zhang M-J et al. (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810–1819PubMedGoogle Scholar
  21. Ganesan TS, Rassool R, Guo A-P et al. (1986) Rearrangement of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood 68:957–960PubMedGoogle Scholar
  22. Gewirtz AM (1992) Therapeutic applications of antisense DNA in the treatment of human leukemia. Ann N Y Acad Sci 660:178–187PubMedCrossRefGoogle Scholar
  23. Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092PubMedCrossRefGoogle Scholar
  24. Groffen J, Stephenson JR, Heisterkamp N, Klein A de, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93–99PubMedCrossRefGoogle Scholar
  25. Guardiolo P, Anderson JE, Bandini G et al. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and bone marrow transplantation. Blood 93:2831–2838Google Scholar
  26. Guilhot F, Chastang C, Michallet M et al. (1997) Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223–229PubMedCrossRefGoogle Scholar
  27. Haferlach T, Winkemann M, Nickenig C et al. (1997) Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 97:99–106PubMedCrossRefGoogle Scholar
  28. Hansen JA, Gooley TA, Martin PJ et al. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968PubMedCrossRefGoogle Scholar
  29. Harrison CN, Gale RE, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia does not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417–422PubMedGoogle Scholar
  30. Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 90:850–858PubMedCrossRefGoogle Scholar
  31. Hehlmann R (1998) A chance of cure for every patient with CML? N Engl J Med 338:980–982PubMedCrossRefGoogle Scholar
  32. Hehlmann R, Heimpel H, Hasford J et al. (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 398:398–407Google Scholar
  33. Heim S, Mitelman F (1995) Cancer cytogenetics. Wiley-Liss, New YorkGoogle Scholar
  34. Heisterkamp N, Stephenson JR, Groffen J et al. (1983) Localization of the c-abl oncogene adjactent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239–242PubMedCrossRefGoogle Scholar
  35. Heisterkamp N, Jenster G, Hoeve J ten, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253PubMedCrossRefGoogle Scholar
  36. Hochhaus A, Reiter A, Skladny H et al. (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88:2236–2240PubMedGoogle Scholar
  37. Hochhaus A, Reiter A, Saussele S et al. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95:62–66PubMedGoogle Scholar
  38. Johansson B, Fioretos T, Billström R, Mitelman F (1996) Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia 10: 1134–1138PubMedGoogle Scholar
  39. Kantarjian HM, Keating MJ, Talpaz M (1987) Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 83:445–454PubMedCrossRefGoogle Scholar
  40. Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122:254–261PubMedGoogle Scholar
  41. Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050PubMedGoogle Scholar
  42. Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035–1042PubMedCrossRefGoogle Scholar
  43. Kramer A, Horner S, Wilier A et al. (1999) Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci USA 96:2087–2092PubMedCrossRefGoogle Scholar
  44. Lange W, Cantin EM, Finke J, Dolken G (1993) In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7:1786–1794PubMedGoogle Scholar
  45. Lengfelder E, Berger U, Hehlmann R (2000) Inteferon-α in polycythemia vera. Ann Hematol 79:103–105PubMedCrossRefGoogle Scholar
  46. Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384PubMedGoogle Scholar
  47. Melo JV, Myint H, Galton DAG, Goldman JM (1994) P190 BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia 8: 208–211PubMedGoogle Scholar
  48. Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma [Suppl 1] 11:11–15CrossRefGoogle Scholar
  49. Nanjangud G, Kadam PR, Saikia T et al. (1994) Karyotypic findings as an independent prognostic marker in chronic myeloid leukemia blast crisis. Leuk Res 18: 385–392PubMedCrossRefGoogle Scholar
  50. Nowell PC, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497Google Scholar
  51. Pane F, Frigeri F, Sindona M et al. (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410–2414 [published erratum appears in Blood 1997 Jun 1;89(11): 4244]PubMedGoogle Scholar
  52. Petrides PE, Beykirch MK, Trapp O (1998) Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur J Hematol 61:71–76CrossRefGoogle Scholar
  53. Raanani P, Dazzi F, Sohal J et al. (1997) The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99:945–950PubMedCrossRefGoogle Scholar
  54. Radich JP, Gehly G, Gooley T et al. (1995) Polymerase chain-reaction detection for the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implication in 346 patients. Blood 85:2632–2640PubMedGoogle Scholar
  55. Rhee F van, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC (1996) pi90 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 87:5213–5217PubMedGoogle Scholar
  56. Reiter A, Skladny H, Hochhaus A et al. (1997) Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol 97:86–93PubMedCrossRefGoogle Scholar
  57. Reiter A, Sohal J, Kulkarni S et al. (1998) Consistent fusion of ZNF198 to fibroblast growth factos receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92:1735–1742PubMedGoogle Scholar
  58. Reiter A, Hehlmann R, Goldman JM, Cross NC (1999) The 8p11 myeloproliferative syndrome. Med Klin 94:207–210CrossRefGoogle Scholar
  59. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293PubMedCrossRefGoogle Scholar
  60. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340PubMedCrossRefGoogle Scholar
  61. Schoch C, Schnittger S, Bursch S et al. (2002) Comparison of chromosome banding analysis, interphase- and hyper-metaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 16:53–59PubMedCrossRefGoogle Scholar
  62. Sill H, Goldman JM, Cross NC (1995) Homozygous deletions of the pl6 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013–2016PubMedGoogle Scholar
  63. Sokal JE, Cox EB, Baccarani M et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63:789–799PubMedGoogle Scholar
  64. Statistisches Bundesamt (1997) Statistisches Bundesamt: Sterbefälle nach Todesursachen in Deutschland. Einzelnachweis. Statistisches Bundesamt, WiesbadenGoogle Scholar
  65. Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1263PubMedCrossRefGoogle Scholar
  66. Tefferi A, Solberg L, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141–149PubMedCrossRefGoogle Scholar
  67. Temerinac S, Klippel S, Strunck E et al. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95:2569–2576PubMedGoogle Scholar
  68. Thiele J, Kvasnicka HM (2000) Polyglobulie versus Polycythemia vera. Pathologe 21:24–30PubMedCrossRefGoogle Scholar
  69. Virchow R (1845) Weisses Blut. Frorieps Notizen 36:151–156Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Torsten Haferlach
  • Susanne Schnittger
  • Claudia Schoch

There are no affiliations available

Personalised recommendations